Production (Stage)
Elevation Oncology, Inc.
ELEV
$0.3817
$0.00150.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.77% | 22.73% | 9.81% | 15.95% | -11.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.85% | 33.93% | 21.14% | 11.48% | -15.20% |
| Operating Income | -9.85% | -33.93% | -21.14% | -11.48% | 15.20% |
| Income Before Tax | -32.81% | -32.15% | -21.12% | -3.41% | 37.28% |
| Income Tax Expenses | -45.45% | 0.00% | 9.09% | 120.00% | 120.00% |
| Earnings from Continuing Operations | -32.73% | -32.12% | -21.11% | -3.47% | 37.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.73% | -32.12% | -21.11% | -3.47% | 37.24% |
| EBIT | -9.85% | -33.93% | -21.14% | -11.48% | 15.20% |
| EBITDA | -9.91% | -34.03% | -21.20% | -11.55% | 15.21% |
| EPS Basic | -16.21% | 5.21% | 13.12% | 50.21% | 71.38% |
| Normalized Basic EPS | 2.80% | 5.25% | 13.09% | 50.20% | 62.76% |
| EPS Diluted | -16.21% | 5.21% | 13.12% | 50.21% | 71.38% |
| Normalized Diluted EPS | 2.80% | 5.25% | 13.09% | 50.20% | 62.76% |
| Average Basic Shares Outstanding | 14.21% | 39.39% | 39.40% | 107.77% | 119.37% |
| Average Diluted Shares Outstanding | 14.21% | 39.39% | 39.40% | 107.77% | 119.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |